Intrexon designs and produces novel and enhanced biological products and processes across multiple industry sectors, including human therapeutics, protein production, industrial products, agricultural biotechnology and animal science. The company is based in Germantown, MD. It closed a $150M Series F financing that it intends to use to establish additional exclusive channel collaborations in its core sectors: Healthcare, Food, Energy and Environment. Intrexon also plans to continue developing its technology platforms and to expand sales and marketing and research and development efforts. Backers on the Series F included Randal J. Kirk and Third Security, LLC, along with new undisclosed investors. The article references a prior $100M Series E financing closed in May 2011. Intrexon is a privately held synthetic biology company founded in 1998 with facilities in Maryland, Virginia, North Carolina and California. The firm’s stated mission is to redefine the product development cycle by reducing the time, cost, and technical risks in engineering biological and cellular systems. It focuses on scalable engineering of rationally designed complex transgenes and claims unmatched control over living cells across five divisions. Intrexon holds over 400 patents and patent applications and works with key channel partners to deliver products. Financially, the company completed a $17 million offering from a single investor, which the article says adds to $128 million in prior financing. The company positions its platform to redefine industrial synthetic biology. Intrexon develops modular DNA control systems and the UltraVector transgene engineering platform used to construct complex transgenes. Its technology supports activities across human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company has launched multiple commercial divisions (AgBio, Animal Science, Protein Production, Human Therapeutics, Industrial Products, and UltraVector) and completed the acquisitions of Agarigen and Neugenesis this year. Intrexon announced an exclusive channel partnership with ZIOPHARM Oncology earlier in the year. The company says the new funding will provide working capital for its commercial divisions and support expansion of the UltraVector platform. Intrexon has raised more than $259 million in total capital to date.

Total raised

$267M

Funding rounds

3

Latest round

Series F

Latest activity

May 2013